M3 Global Research Launches Compliance Program for French Sunshine Act Loi Bertrand

New Program to Comply with French Law

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
M3 Global Research is the only ISO 26362 certified healthcare panel in the world and 20 out of 20 of the top global pharmaceutical manufacturers trust M3 Group companies with their market research, clinical trials, and marketing.

Washington, DC (PRWEB) March 28, 2014

M3 Global Research, part of M3 Group and one of the largest healthcare data collection companies in the world, has implemented a new compliance program for data collection, developed for French healthcare professionals in accordance with the French Sunshine Act Loi Bertrand. Originally passed in 2011, this Sunshine Act is designed to provide transparency for both direct and indirect payments made by pharmaceutical manufacturers and marketers to the companies that provide services to them, as well as to healthcare professionals and healthcare associations. While most Sunshine Acts exempt market research, the French Ministry of Social Affairs and Health has determined that under this law, market research falls within an agreement framework that requires disclosure and reporting.                

Through this new compliance program, every French healthcare professional who enters a study with M3 will submit their agreement to comply with Loi Bertrand. These healthcare professionals include: physicians, dentists, nurses, pharmacists, optometrists, therapists, podiatrists, medical technicians, dieticians, audiologists, chiropractors and psychologists. M3 Global Research will obtain each healthcare professional’s name, hospital name, address, city, title, profession and specialty, as well as the date of agreement. This information is then submitted to the secure Transparence Sante disclosure site (https://www.entreprises-transparence.sante.gouv.fr) within 15 days of obtaining the agreement.

In creating this program, M3 Global Research received advisory information from EphMRA, CASRO, and ASOCS. To facilitate a smooth program launch, M3 has been corresponding with its ISO 26362 certified, opted-in French market research panel about the changes, so they are fully prepared for the agreement framework and disclosure requirement. M3 will provide this compliance reporting program to its agency clients and end client pharmaceutical manufacturers as a standard practice in fielding.

M3 Global Research is the only ISO 26362 certified healthcare panel in the world and 20 out of 20 of the top global pharmaceutical manufacturers trust M3 Group companies with their market research, clinical trials, and marketing.

About M3 Group                                                                                                                        
The M3 Group operates in the US, Asia, and Europe with over 2.5 million physician members globally via its physician websites such as m3.com, http://www.mdlinx.com, http://research.m3.com, http://www.doctors.net.uk, http://www.medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, and Seoul.

M3 Group Sites
research.m3.com mdlinx.com doctors.net.uk networksinhealth.com mdlinx.pdr.net
thesmartestdoc.com career.mdlinx.com medlive.cn medigate.net


Contact